About this item:

14 Views | 6 Downloads

Author Notes:

Catherine Lavau, DVM, PhD*, Research Drive, LSRC building, Room C-243, Box 3813, Durham, NC 27710, Phone: (919) 684 0575 Email: catherine.lavau@duke.edu

Daniel S. Wechsler, MD, PhD*, HSRB W344, 1760 Haygood Dr NE, Atlanta, GA 30322, Phone: (404) 727-3620, Email: dan.wechsler@emory.edu

The authors contributed equally to the manuscript.

None of the authors has any direct or indirect commercial financial incentive associated with publishing this article. None of the authors has an affiliation with any organization that, to our knowledge, has a direct interest in the subject matter discussed. The Wechsler Laboratory received financial support from Karyopharm, Inc. several years prior to performing the work described in this manuscript, but no Karyopharm products were used for the studies described here.


Research Funding:

This work was supported by an American Society of Hematology Research Training Award for Fellows (WKA), Hyundai Hope on Wheels Young Investigator Award (WKA and CPL), Hyundai Hope On Wheels Scholar Award (CPL and DSW), the Duke Cancer Institute (CPL), a NIH R03 grant (1R03CA191983–01A1, CPL), Alex’s Lemonade Stand Young Investigator Award (JLH), Pablove Foundation (JLH), Pediatric Cancer Research Foundation (JLH), NHLBI T32 5T32HL007057–37 (WKA), NHLBI T32 5T32HL007057–40 (SKS), a St. Baldrick’s Foundation Research Award (DSW), and the Schiffman Family Foundation. CPL is an INSERM scientist.

CRM1 plasmids containing mutants in the NUP214 binding region were generously provided by Ralph Kehlenbach and Sarah Port. Pritha Bagchi, PhD and the Emory Integrated Proteomics Core provided assistance with BioID2 Mass Spectrometry.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology

Fusion of the CRM1 nuclear export receptor to AF10 causes leukemia and transcriptional activation of HOXA genes

Journal Title:



Volume 35, Number 3


, Pages 876-880

Type of Work:

Article | Post-print: After Peer Review


To study leukemogenesis, mice were transplanted with HPCs transduced with fusions using a bicistronic MSCV-IRES-eGFP vector in order to track GFP-positive transduced cells. Both cohorts of CRM1-AF10 (n=13) and CRM1Δ-AF10 (n=8) transplanted mice initially displayed similar percentages of GFP-expressing peripheral blood leukocytes, indicating comparable engraftment (Supplementary Figure 1A). Mice were observed for 450 days, during which 69% of CRM1-AF10 mice developed myeloid leukemia with a median survival of 348 days post-transplant, while 100% of CRM1Δ-AF10 mice developed leukemia with a median survival of 112.5 days post-transplant. In comparison, mice transplanted with CALM-AF10 transduced progenitors developed leukemia within 98 to 200 days (median survival 160 days) (Figure 1D). Of note, mice transplanted with HPCs transduced with either full length wild type CRM1 (n=5) or truncated CRM1Δ (aa 1–1028) (n=5) never developed leukemia (>570 days of observation, data not shown). Both CRM1-AF10 and CRM1Δ-AF10 leukemia mice showed signs of hyperleukocytosis, including splenomegaly (Supplementary Figure 1B) and invasion of bone marrow with GFP-positive leukemia blasts expressing the myeloid markers Mac-1 and Gr-1 (Supplementary Figure 1C). As we have reported for CALM-AF10 leukemia [5], CRM1-AF10 and CRM1Δ-AF10 blasts rarely expressed the pan-B lymphoid marker B220. Leukemic bone marrow blasts from CALM-AF10, CRM1-AF10 or CRM1Δ-AF10 mice expressed similar levels of Hoxa and Meis1 transcripts (Supplementary Figure 1D). Secondary leukemias could be induced by transplanting leukemic blasts recovered from either CRM1-AF10 or CRM1Δ-AF10 leukemic mice (Supplementary Figure 2).
Export to EndNote